Associated tags: Apis, English, COVID-19 testing, Genetics, COVID-19, USD, Social responsibility, ACT, Genomics, Pharmaceutical industry, Cancer
Locations: MIDDLE EAST, LONDON, CHINA, QUARRY BAY, HK, US, HONG KONG, UNITED KINGDOM
HONG KONG, April 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced unaudited financial results for the fourth quarter and full year ended December 31, 2023, along with recent business updates.
Key Points:
- HONG KONG, April 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced unaudited financial results for the fourth quarter and full year ended December 31, 2023, along with recent business updates.
- Revenue from continuing operations of US$5.4 million in the fourth quarter 2023, an increase of 90.8% as compared to the fourth quarter 2022.
- Adjusted EBITDA from continuing operations of US$(6.2) million in the fourth quarter 2023.
- Adjusted net loss attributable to equity shareholders of Prenetics was US$(28.4) million for the year ended December 31, 2023.
MOU,
University,
University of Oxford,
Partnership,
Associate,
MRI,
CAT,
ECG,
Health,
Rejuvenation,
SpaceX,
Ageing,
Research,
Longevity,
Space research,
NASA,
ISS DUBAI, United Arab Emirates, Feb. 09, 2024 (GLOBE NEWSWIRE) -- UAE Space Agency – Prenetics Global Limited (NASDAQ:PRE), a leading genomics-driven health sciences company, announces the signing of a Memorandum of Understanding (MOU), that paves the way for a strategic investment in Metavisionaries and a pioneering five-year research agreement with them and their partners Space Application Services through their Metaspace Venture. The parties will also establish a Space Innovation Lab within the UAE Space Agency. The inaugural Prenetics research cube is scheduled to on-board the SpaceX to the ISS in Q4 of 2024.
Key Points:
- The parties will also establish a Space Innovation Lab within the UAE Space Agency.
- The inaugural Prenetics research cube is scheduled to on-board the SpaceX to the ISS in Q4 of 2024.
- Concurrently, Danny Yeung, CEO of Prenetics will join the Board of Directors at Metavisionaries, fortifying its strategic vision.
- I’m excited to contribute to Prenetics' mission and to translate space research into health innovations on Earth,” said Dr. James L. Green.
Retrieved on:
Monday, November 20, 2023
HONG KONG, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced financial results for the third quarter ended September 30, 2023, along with recent business updates.
Key Points:
- HONG KONG, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced financial results for the third quarter ended September 30, 2023, along with recent business updates.
- Cash and other short-term assets1 of US$105.2 million as of September 30, 2023; with an additional $79.1 million of cash with Insighta, our 50/50 joint venture in early cancer detection with Professor Dennis Lo
"During the third quarter, we made further progress on our transformation.
- Insighta is accounted for using equity method and is not consolidated in the results of Prenetics.
- Insighta’s 500-participants clinical trial for early cancer detection is in progress, and is expected to have full results for publication in the first half of 2024
Retrieved on:
Wednesday, November 1, 2023
HONG KONG, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading-genomics-driven health sciences company today announced that it will proceed with a reverse stock split of its outstanding ordinary shares at a ratio of 1-for-15.
Key Points:
- HONG KONG, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading-genomics-driven health sciences company today announced that it will proceed with a reverse stock split of its outstanding ordinary shares at a ratio of 1-for-15.
- The reverse stock split is expected to become effective on or around November 13, 2023, subject to confirmation by NASDAQ.
- The reverse stock split is intended to bring the Company into compliance with the minimum $1.00 per share requirement for continued listing on NASDAQ.
- The Company's transfer agent, Continental Stock Transfer & Trust Company ("Continental"), will serve as the transfer agent for the Reverse Stock Split.
Retrieved on:
Friday, September 15, 2023
HONG KONG, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced financial results for the second quarter ended June 30, 2023, along with recent business updates.
Key Points:
- HONG KONG, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced financial results for the second quarter ended June 30, 2023, along with recent business updates.
- Prenetics provided US$100m in consideration, with US$80m in cash and US$20m of shares in Prenetics.
- ACT Genomics is expected to launch a 500-gene panel and a 100-gene panel comprehensive genomic profiling “liquid” biopsy test by the fourth quarter of 2023.
- Significant improvement in operational efficiency and cost optimization, reducing adjusted EBITDA from continuing operations from a loss of US$(9.8) million in the first quarter of 2023 to US$(5.3) million in the current quarter with further reductions expected in the second half of 2023.
ACT,
Faculty,
DNA,
Commercialization,
Communications and Information Technology Commission (Saudi Arabia),
UBS AG,
Workflow,
Survival,
Holy Grail,
Liquid biopsy,
Clinical trial,
Cancer,
Liver,
Global health,
Innovation,
Genomics,
Chinese University of Hong Kong,
Mother,
Science,
University of Hong Kong,
Plasma,
Death,
Chinese,
University of Toronto Faculty of Medicine,
Royal Medal,
CUHK,
UBS,
Ageing,
Lasker,
Research,
Health,
Royal Society,
NIPT,
Dean (education),
Cryptocurrency,
Video game,
Film industry,
Pharmaceutical industry,
Vaccine,
Cirina,
Illumina,
Medicine -- Insighta is a 50/50 Joint Venture by Prenetics and Professor Dennis Lo.
Key Points:
- -- Insighta is a 50/50 Joint Venture by Prenetics and Professor Dennis Lo.
- -- By 2030, the early cancer detection screening opportunity is estimated to be US$6bn in Asia on an annual basis.
- The joint venture will be governed by a six-person board of directors composed of three directors from each side, with Prof.
- From prevention (CircleDNA) and early detection (Insighta) to treatment (ACT), our innovative approach promises to significantly raise the bar in healthcare."
ACT,
Faculty,
DNA,
Commercialization,
Communications and Information Technology Commission (Saudi Arabia),
UBS AG,
Workflow,
Survival,
Holy Grail,
Liquid biopsy,
Clinical trial,
Cancer,
Liver,
Global health,
Innovation,
Genomics,
Chinese University of Hong Kong,
Mother,
Science,
University of Hong Kong,
Plasma,
Chinese,
University of Toronto Faculty of Medicine,
Royal Medal,
Capital,
CUHK,
UBS,
Ageing,
Lasker,
Research,
Health,
Royal Society,
NIPT,
Dean (education),
Film industry,
Cryptocurrency,
Pharmaceutical industry,
Medical imaging,
Cirina,
Illumina,
Medicine Transaction Terms - Prenetics will receive a 50% equity stake, while Prof. Lo’s party will also receive a 50% equity stake.
Key Points:
- Transaction Terms - Prenetics will receive a 50% equity stake, while Prof. Lo’s party will also receive a 50% equity stake.
- The joint venture will be governed by a six-person board of directors composed of three directors from each side, with Prof.
- Lo, as the Associate Dean (Research) of the Faculty of Medicine at the Chinese University of Hong Kong, consistently demonstrates outstanding academic leadership.
- Lo published in 20224, will be the technology utilized for multi-cancer early detection screening for Insighta.
ACT,
Fintech,
Institute of Corporate Directors,
Sequoia Capital,
Genomics,
Ernst & Young,
Liquid biopsy,
Joel,
Coronavirus Scientific Advisory Board,
Pine Labs,
Groupon,
FDA,
Health,
Management,
Pharmaceutical industry,
Fave HONG KONG, June 05, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics and precision oncology company, today announced financial results for the first quarter ended March 31, 2023, along with recent business updates.
Key Points:
- HONG KONG, June 05, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics and precision oncology company, today announced financial results for the first quarter ended March 31, 2023, along with recent business updates.
- Joel Neoh, highly successful serial entrepreneur, joins Prenetics as Chief Consumer Officer and Managing Director for CircleDNA.
- ACT Genomics is set to launch a liquid biopsy version of its comprehensive genomic profiling test by the fourth quarter of 2023.
- Danny Yeung, Chief Executive Officer and Co-founder of Prenetics, said, “2023 is a year of evolution for Prenetics as we execute our consumer health and clinical testing business strategy.
ACT,
AstraZeneca,
Cancer,
Acquisition,
United Kingdom,
Workforce,
Medicine,
Chairperson,
Genomics,
Chinese University of Hong Kong,
Chinese,
Patient,
Nature,
Investment,
EBITDA,
COVID-19,
FDA,
Communication,
Growth,
Coronavirus Scientific Advisory Board,
Social responsibility,
Cryptocurrency,
Pharmaceutical industry,
Medical imaging,
Vaccine,
Renewable energy,
Video game,
Insurance,
Bank,
Artisan -- Cash and other short-term assets of US$242.1 million as of December 31, 2022
Key Points:
- -- Cash and other short-term assets of US$242.1 million as of December 31, 2022
-- Embarked on a new business strategy focused on precision oncology, as the Company exits the COVID-19 testing business.
- Furthermore, I am immensely optimistic with our new business strategy in precision oncology.
- Prenetics is focusing its business strategy to genomics and precision oncology, and is dedicated to transforming patients' care through advanced genomic and molecular technologies.
- -- Adjusted EBITDA was US$12.1 million for the fourth quarter 2022 compared to US$(5.9) million for the fourth quarter 2021.
ACT,
AstraZeneca,
Cancer,
Acquisition,
United Kingdom,
Workforce,
Medicine,
Chairperson,
Depreciation,
Genomics,
Chinese University of Hong Kong,
Chinese,
Nature,
Investment,
EBITDA,
COVID-19,
FDA,
Communication,
Growth,
Coronavirus Scientific Advisory Board,
Social responsibility,
Cryptocurrency,
Bank,
Pharmaceutical industry,
Medical imaging,
Vaccine,
Renewable energy,
Video game,
Insurance,
Artisan Revenue was US$52.3 million for the fourth quarter 2022 compared to US$64.7 million for the fourth quarter 2021, a decrease of 19.2% year-over-year.
Key Points:
- Revenue was US$52.3 million for the fourth quarter 2022 compared to US$64.7 million for the fourth quarter 2021, a decrease of 19.2% year-over-year.
- Gross margin was 51.6% for the fourth quarter 2022 compared to 36.7% for the fourth quarter 2021.
- Profit from operations was US$4.6 million for the fourth quarter 2022 compared to loss from operations of US$30.8 million for the fourth quarter 2021.
- Adjusted EBITDA3 was US$12.1 million for the fourth quarter 2022 compared to US$(5.9) million for the fourth quarter 2021.
